Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys

New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and Cure

(2021) Hui Li et al.   JOURNAL OF VIROLOGY

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

(2021) Lawrence Corey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity

(2020) Julia Niessl et al.   NATURE MEDICINE

Novel Antiretroviral Agents

(2020) Mary C. Cambou et al.   Current HIV/AIDS Reports

T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers

(2020) Prabhu S. Arunachalam et al.   NATURE MEDICINE

Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody

(2020) Mangaiarkarasi Asokan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti–HIV-1 IgG1 antibodies in vivo

(2020) Pengfei Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunotherapy during the acute SHIV infection of macaques confers long-term suppression of viremia

(2020) Yoshiaki Nishimura et al.   JOURNAL OF EXPERIMENTAL MEDICINE

OMIP-052: An 18-Color Panel for Measuring Th1, Th2, Th17, and Tfh Responses in Rhesus Macaques

(2019) Mitzi M. Donaldson et al.   CYTOMETRY PART A

Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic

(2019) Marina Caskey et al.   NATURE MEDICINE

Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes

(2019) Sean P. O’Brien et al.   PLoS Pathogens

Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study

(2019) Yehuda Z. Cohen et al.   PLoS One

Principles Governing Establishment versus Collapse of HIV-1 Cellular Spread

(2019) Jason M. Hataye et al.   Cell Host & Microbe

New-Generation High-Potency and Designer Antibodies: Role in HIV-1 Treatment

(2018) Lucio Gama et al.   Annual Review of Medicine

Central Nervous System Inflammation and Infection during Early, Nonaccelerated Simian-Human Immunodeficiency Virus Infection in Rhesus Macaques

(2018) Denise C. Hsu et al.   JOURNAL OF VIROLOGY

Analysis of complement-mediated lysis of SIV and SIV-infected cells reveals sex differences in vaccine-induced immune responses in Rhesus macaques

(2018) Leia K. Miller-Novak et al.   JOURNAL OF VIROLOGY

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults

(2018) Martin R. Gaudinski et al.   PLOS MEDICINE

HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies

(2018) Simone I. Richardson et al.   PLoS Pathogens

Follicular Dendritic Cells of Lymph Nodes as Human Immunodeficiency Virus/Simian Immunodeficiency Virus Reservoirs and Insights on Cervical Lymph Node

(2018) Rajnish S. Dave et al.   Frontiers in Immunology

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

(2018) Pilar Mendoza et al.   NATURE

Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

(2018) Yotam Bar-On et al.   NATURE MEDICINE

Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies

(2018) Matthew S. Parsons et al.   Retrovirology

SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772)

(2018) Ganesh Raghu et al.   EUROPEAN RESPIRATORY JOURNAL

Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers

(2018) Matthias G. Pauthner et al.   IMMUNITY

Recent progress in broadly neutralizing antibodies to HIV

(2018) Devin Sok et al.   NATURE IMMUNOLOGY

Use of broadly neutralizing antibodies for HIV-1 prevention

(2017) Amarendra Pegu et al.   IMMUNOLOGICAL REVIEWS

Anti-retroviral antibody FcγR-mediated effector functions

(2017) Stylianos Bournazos et al.   IMMUNOLOGICAL REVIEWS

Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys

(2017) Boris Julg et al.   JOURNAL OF VIROLOGY

Early antibody therapy can induce long-lasting immunity to SHIV

(2017) Yoshiaki Nishimura et al.   NATURE

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

(2017) Marina Caskey et al.   NATURE MEDICINE

HIV Drug Resistance — An Emerging Threat to Epidemic Control

(2017) Chris Beyrer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques

(2017) Ling Xu et al.   SCIENCE

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial

(2017) Kenneth H. Mayer et al.   PLOS MEDICINE

Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth

(2016) Jinghe Huang et al.   IMMUNITY

Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design

(2016) Young D. Kwon et al.   JOURNAL OF VIROLOGY

Envelope residue 375 substitutions in simian–human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques

(2016) Hui Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo

(2016) C.-L. Lu et al.   SCIENCE

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection

(2016) Kshitij Wagh et al.   PLoS Pathogens

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults

(2015) J. E. Ledgerwood et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs

(2015) Diane L. Bolton et al.   JOURNAL OF VIROLOGY

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

(2015) Marina Caskey et al.   NATURE

Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env

(2015) Young Do Kwon et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

(2015) Rebecca M. Lynch et al.   Science Translational Medicine

Activation and lysis of human CD4 cells latently infected with HIV-1

(2015) Amarendra Pegu et al.   Nature Communications

Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env

(2015) Young Do Kwon et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity

(2014) Stylianos Bournazos et al.   CELL

Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes

(2014) Rui Kong et al.   JOURNAL OF VIROLOGY

Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo

(2014) R. S. Rudicell et al.   JOURNAL OF VIROLOGY

Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex

(2014) Devin Sok et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor

(2014) A. Pegu et al.   Science Translational Medicine

A Novel Assay for Antibody-Dependent Cell-Mediated Cytotoxicity against HIV-1- or SIV-Infected Cells Reveals Incomplete Overlap with Antibodies Measured by Neutralization and Binding Assays

(2012) M. D. Alpert et al.   JOURNAL OF VIROLOGY

A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples

(2010) Margaret E. Ackerman et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

(2010) X. Wu et al.   SCIENCE

Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1

(2009) Brandon F. Keele et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Characterization of the Follicular Dendritic Cell Reservoir of Human Immunodeficiency Virus Type 1

(2008) B. F. Keele et al.   JOURNAL OF VIROLOGY

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

(2008) B. F. Keele et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA